Predesigned siRNA

MISSION^® Predesigned siRNA were created using the proprietary Rosetta Inpharmatics siRNA Design algorithm in an exclusive partnership with Merck & Co. The Rosetta siRNA Design Algorithm utilizes Position-Specific Scoring Matrices and knowledge of the seed region to predict the most specific and effective sequences for your target genes. The algorithm’s rules were developed utilizing empirical data collected from gene silencing experiments carried out over three years.

Product Benefits

• Best-in-class, guaranteed gene silencing
• Efficient knockdown of low abundance messages
• Simplified transfection optimization with 11 Positive Control siRNA
• Distinguish sequence-specific silencing from non–specific effects with 8 negative control siRNA
• Hundreds of functionally-validated predesigned siRNA

Product Features

• Species: Human, Mouse & Rat
• Quantities: 2 (10 nmol), 5 (25 nmol) & 10 (50 nmol) OD
• Purification: Desalt or HPLC
• Sequence Form: 21mer duplexes with dTdT overhangs
• Quality Control: 100% mass spectrometry*
• Format: Supplied dry in tubes

*Depending on manufacturing site, PAGE may be used to assess siRNA duplexes.

Predesigned Guarantee

At least two of three purchased MISSION^® Predesigned siRNA targeting the same gene will reduce target mRNA levels by 75%, in cultured cells, when transfected at a concentration of ≥30 nM. If two of the siRNA do not knock down the target gene by 75%, we will provide three additional siRNA for that gene, free of charge. If there are no more siRNA for that gene or all siRNA fail to knock down the target gene by 75%, we will refund the purchase price.
Receipt of appropriate supporting data for transfection efficiency is required for the guarantee to apply. Appropriate supporting data for transfection efficiency would include qPCR data comparing target mRNA levels of a MISSION Positive Control siRNA (GAPDH, MAPK1, TP53, etc.), transfected at ≥30 nM, to an appropriate negative control (such as mock transfection, a scrambled siRNA sequence, or MISSION Universal Negative Control siRNA), demonstrating knockdown of the target mRNA of 75%.
Due to the variability of antibodies and protein half-lives, we are unable to accept data from protein-based detection methods.

 Product Pools

A popular pooled format is 4 duplexes at 5 nmol each combined into one tube (20 nmol pooled) plus the exact same 4 duplexes also at 5 nmol each in separate tubes (another 20 nmol individual). However, our sophisticated liquid handlers allow for a wide range of other possibilities. For feasibility review of your specific needs, contact sirnarequest@sial.com.

Validated siRNA

Many common gene targets have been validated for ≥75% mRNA knockdown (Figure 1 for example data and the table for a list of commonly-ordered, validated siRNA by gene symbol). Validated siRNA are suitable for transfection optimization and as positive controls.

Figure 1. HeLa cells transfected with predesigned siRNA at a concentration of 30 nM. The percentage remaining gene expression levels were measured via qPCR 48 hours after transfection (relative to mock). Data represents the mean of four biological replicates.

Validated siRNA by Gene Symbol
ABCC1	CDC7	DYRK1A	IGFBP4	MLH1	PIK3R4	PRPS1	SIK2
ACP1	CDC73	DYRK1B	IL6ST	MSH2	PIM2	PRSS23	SLC16A1
ACP2	CDK1	EEF2K	ILK	MST4	PIN1	PSEN1	SLC25A17
ACVR1	CDK11B	EIF2AK4	IMPA2	MTA2	PINK1	PSEN2	SLC2A1
ACVR1B	CDK17	EIF4A3	INPPL1	MTM1	PIP4K2B	PSMA7	SLC30A1
ADAM10	CDK2	EMR2	IP6K1	MTMR1	PIP5K1A	PSMB4	SLK
ADAM12	CDK4	ENPP1	IP6K2	MTMR2	PKN2	PSMB5	SMU1
ADAM15	CDK5	EPHA5	IPMK	MTMR3	PLAUR	PSMB6	SNRK
ADIPOR1	CDK6	EPHB4	IRAK1	MTMR6	PLK1	PSPH	SORT1
ADIPOR2	CDK7	F3	IRAK4	MTOR	PLK4	PTK2	SRC
ADRBK1	CDK8	FADD	ITPK1	NADK	POLK	PTP4A1	SRPK1
AKT1	CDK9	FDFT1	JAK1	NCSTN	PPAP2C	PTPLA	ST7
AKT2	CDKL5	FER	JUND	NDRG1	PPAT	PTPN1	STAT3
ALPL	CDKN1B	FMNL1	JUP	NEDD8	PPM1D	PTPN11	STK16
APP	CDKN3	FURIN	LANCL1	NEK2	PPME1	PTPN12	STK24
ARAF	CELSR1	FYN	LATS1	NEK6	PPP1CA	PTPN14	STK3
ARHGDIA	CERK	FZD4	LDHA	NEK7	PPP1CB	PTPN23	STYX
ATF1	CHEK1	FZD5	LEPR	NEK9	PPP1CC	PTPN9	TAOK1
ATM	CHUK	FZD6	LGALS3	NET1	PPP1R11	PTPRE	TAOK3
ATP6V0C	CKS2	GLTSCR2	LIMK2	NF1	PPP1R12A	PTPRF	TBK1
ATR	CLPP	GPRC5A	LRP5	NLN	PPP1R2	PTPRJ	TEK
AURKB	CPE	GRB2	LRP6	NME1	PPP1R3C	PTPRK	TESK1
AXIN1	CPT1A	GRK6	LTBR	NME1-NME2	PPP1R7	PTPRS	TFRC
AXL	CRKL	GRN	LYN	NME2	PPP2CA	RAB22A	TGFBR1
BACE1	CSK	GSK3B	MAD2L1	NOTCH2	PPP2CB	RAF1	TGM1
BACE2	CSNK2A1	HADHB	MANF	NPR1	PPP2R1A	RAP1B	TGM2
BAD	CTNNB1	HBEGF	MAP2K2	NR1H2	PPP2R2A	RARG	THRA
BAG1	CTSA	HCG 1757335	MAP2K5	NR1H3	PPP2R5A	RB1	TK1
BCAT1	CXCR4	HDAC1	MAP3K3	NR2C2	PPP2R5D	RELA	TKT
BIRC5	CXCR7	HDAC2	MAP3K4	NR2F2	PPP2R5E	RHOA	TLR4
BMP6	CYLD	HECTD1	MAPK14	NUP85	PPP3CC	RIOK3	TM4SF1
BMPR1A	DAD1	HIPK2	MAPK3	OCRL	PPP5C	RIPK1	TNFRSF10B
BRAF	DAPK3	HIPK3	MAPK6	OXSR1	PPP6C	RIPK2	TRIM28
BUB1	DCN	HPRT1	MAPK8	PAK2	PREPL	RNF10	TWF1
BUB1B	DDR1	HSPA1A	MAPK9	PASK	PRKACA	RNF5	TYRO3
CASK	DGKA	HSPA1B	MAPKAPK5	PBK	PRKACB	ROCK1	VEGFC
CCL2	DMBT1	HSPB8	MARK3	PCNA	PRKAG1	ROCK2	VIPR1
CCNA2	DNMT1	HTRA1	MASTL	PCSK9	PRKAR1A	ROR2	VRK2
CCNC	DUSP10	HUNK	MBTPS1	PDE8A	PRKAR2A	RPS6KA3	WNK1
CCND1	DUSP11	ICAM1	MELK	PDGFRB	PRKCA	RPS6KA4	YES1
CCT2	DUSP12	ICK	MET	PDK1	PRKCI	RPS6KB1	ZMPSTE24
CD63	DVL2	IGF1R	MIF	PGK1	PRKCZ	RYK
CD82	DVL3	IGF2R	MINPP1	PHPT1	PRKDC	SHC1

Select Citations

1. Yang X, Sierant M, Janicka M, Peczek L, Martinez C, Hassell T, Li N, Li X, Wang T, Nawrot B. 2012. Gene Silencing Activity of siRNA Molecules Containing Phosphorodithioate Substitutions. ACS Chem. Biol.. 7(7):1214-1220. https://doi.org/10.1021/cb300078e

2. Salma J, McDermott JC. 2012. Suppression of a MEF2-KLF6 Survival Pathway by PKA Signaling Promotes Apoptosis in Embryonic Hippocampal Neurons. Journal of Neuroscience. 32(8):2790-2803. https://doi.org/10.1523/jneurosci.3609-11.2012

3. Gilot D, Le Meur N, Giudicelli F, Le Vée M, Lagadic-Gossmann D, Théret N, Fardel O. RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 Activity. PLoS ONE. 6(3):e18261. https://doi.org/10.1371/journal.pone.0018261

4. Raab M, Kappel S, Krämer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T, et al. 2011. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun. 2(1): https://doi.org/10.1038/ncomms1395

5. Chia KM, Liu J, Francis GD, Naderi A. 2011. A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer. Neoplasia. 13(2):154-166. https://doi.org/10.1593/neo.101324

6. Ramachandran V, Arumugam T, Langley R, Hwang RF, Vivas-Mejia P, Sood AK, Lopez-Berestein G, Logsdon CD. The ADMR Receptor Mediates the Effects of Adrenomedullin on Pancreatic Cancer Cells and on Cells of the Tumor Microenvironment. PLoS ONE. 4(10):e7502. https://doi.org/10.1371/journal.pone.0007502

7. Santra MK, Wajapeyee N, Green MR. 2009. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature. 459(7247):722-725. https://doi.org/10.1038/nature08011

8. Meng W, Mushika Y, Ichii T, Takeichi M. 2008. Anchorage of Microtubule Minus Ends to Adherens Junctions Regulates Epithelial Cell-Cell Contacts. Cell. 135(5):948-959. https://doi.org/10.1016/j.cell.2008.09.040

9. Matsubara T, Kida K, Yamaguchi A, Hata K, Ichida F, Meguro H, Aburatani H, Nishimura R, Yoneda T. 2008. BMP2 Regulates Osterix through Msx2 and Runx2 during Osteoblast Differentiation. J. Biol. Chem.. 283(43):29119-29125. https://doi.org/10.1074/jbc.m801774200

10. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, et al. 2008. Genome-Scale RNAi Screen for Host Factors Required for HIV Replication. Cell Host & Microbe. 4(5):495-504. https://doi.org/10.1016/j.chom.2008.10.004

11. Espeseth AS, Huang Q, Gates A, Xu M, Yu Y, Simon AJ, Shi X, Zhang X, Hodor P, Stone DJ, et al. 2006. A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels. Molecular and Cellular Neuroscience. 33(3):227-235. https://doi.org/10.1016/j.mcn.2006.07.003

12. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, et al. 2006. Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions. MCB. 26(24):9377-9386. https://doi.org/10.1128/mcb.01229-06

13. Majercak J, Ray WJ, Espeseth A, Simon A, Shi X, Wolffe C, Getty K, Marine S, Stec E, Ferrer M, et al. 2006. LRRTM3 promotes processing of amyloid-precursor protein by BACE1 and is a positional candidate gene for late-onset Alzheimer's disease. Proceedings of the National Academy of Sciences. 103(47):17967-17972. https://doi.org/10.1073/pnas.0605461103

If additional help is needed, please consult our technical services group at oligotechserv@sial.com.

MISSION is a trademark of Merck KGaA, Darmstadt, Germany and/or its affiliates. Label License.